Description
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
MicrosoftInternetExplorer4
This study is a
randomized, double-blind, placebo-controlled study that will evaluate the
safety and efficacy of dasiglucagon in children between the ages of 7 days and
12 months who have congenital hyperinsulinism. Dasiglucagon will be given as a
subcutaneous infusion while patients are admitted to the hospital. Other
treatments for hyperinsulinism may be changed as allowed while maintaining safe
blood sugar levels. For the second part of the study, patients may be able to
go home on the medication.
For More Information
Contact Us OnlineCall 267-426-9915